PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-7.47%
Both companies show declining cash positions (-7.47% vs TRAW's -7.81%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-7.47%
Similar yoy growth to TRAW's -7.81%. Walter Schloss would note comparable liquidity expansions. Examine capital usage strategies.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.14%
Similar yoy growth to TRAW's -7.31%. Walter Schloss notes comparable short-term expansions. Investigate quality of these assets.
-20.34%
≥ 1.5x TRAW's -7.89%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-20.34%
≥ 1.5x TRAW's -6.25%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
-7.25%
Similar yoy to TRAW's -7.31%. Walter Schloss sees parallel expansions. Evaluate the quality of these assets.
-4.95%
Less than half of TRAW's 13.24%. David Dodd sees a more disciplined AP approach or lower volume.
-36.48%
Higher Short-Term Debt Growth compared to TRAW's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-627.15%
Both TRAW and the company show zero Deferred Revenue (Current) Growth.
-89.58%
Exceeding 1.5x TRAW's -2.19%. Michael Burry suspects ballooning short-term obligations vs. competitor.
-16.33%
Above 1.5x TRAW's -2.73%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-33.33%
Above 1.5x TRAW's -1.73%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
-16.34%
Above 1.5x TRAW's -2.38%. Michael Burry sees a potential leverage warning sign.
No Data
No Data available this quarter, please select a different quarter.
-2.01%
≥ 1.5x TRAW's -0.93%. David Dodd sees higher yoy retained profits than competitor.
100.00%
Less than half of TRAW's -50.00%. David Dodd sees fewer intangible or market-driven swings than competitor.
-100.00%
Higher Other Stockholders' Equity Items Growth compared to TRAW's zero value, indicating worse performance.
-6.40%
0.75-0.9x TRAW's -8.31%. Bill Ackman wonders if competitor is growing equity faster.
-7.25%
Similar yoy to TRAW's -7.31%. Walter Schloss sees parallel expansions in total capital.
No Data
No Data available this quarter, please select a different quarter.
-36.45%
Higher Total Debt Growth compared to TRAW's zero value, indicating worse performance.
7.35%
Similar yoy changes to TRAW's 7.81%. Walter Schloss sees parallel net leverage strategies.